Constantine Tam News Today

In case you missed it, here is a recap of the most popular episodes of OncLive On Air® from 2023.

Researchers found that, despite being heavily immunocompromised, haematology patients generate strong cellular immune responses against SARS-CoV-2 after vaccination, on par with that of healthy individuals.

A look back at some of the top stories for CLL in 2022

Data from four pivotal trials continue to build evidence base for BRUKINSA (zanubrutinib) in B-cell malignancies Pipeline showing promise with early data for BGB-11417, a BCL-2 inhibitor, as monotherapy

This class, with the only drugs ever approved for this rare blood cancer, has been a game changer

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)--Dec 12, 2021--

The new second-generation BTK inhibitor zanubrutinib is a preferred regimen for the treatment of symptomatic Waldenstroms macroglobulinemia.